Isotonic Solution Administration Logistical Testing (SALT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02345486 |
|
Recruitment Status :
Completed
First Posted : January 26, 2015
Results First Posted : October 25, 2019
Last Update Posted : November 13, 2019
|
Sponsor:
Vanderbilt University
Information provided by (Responsible Party):
Todd Rice, Vanderbilt University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The administration of intravenous crystalloids is ubiquitous in the care of the critically ill. Commonly available crystalloid solutions contain a broad spectrum of electrolyte compositions including a range of chloride concentrations. Recent studies of associated higher fluid chloride content with acute kidney injury and mortality but no large, randomized trials have been conducted. In preparation for a large, cluster-randomized, multiple-crossover trial comparing 0.9% sodium chloride to physiologically-balanced isotonic crystalloids (Lactated Ringers or Plasmalyte-A) in intensive care unit patients, this pilot study will enroll all patients admitted to the medical intensive care unit at a single tertiary center for a sixth month period. The primary objective will be to test the ability of an electronic order entry tool to ensure administration of assigned study fluid or record contraindications to assigned study fluid. The pilot study will also demonstrate the feasibility of collecting demographic, severity of illness, fluid management, vital sign, laboratory, acute kidney injury and renal replacement therapy, and outcome data in an automated, electronic fashion.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Kidney Injury | Other: 0.9% sodium chloride Other: Physiologically balanced fluid | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 974 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Isotonic Solution Administration Logistical Testing: Pilot Study for the Isotonic Solutions and Major Adverse Renal Events Trial |
| Study Start Date : | February 2015 |
| Actual Primary Completion Date : | June 2015 |
| Actual Study Completion Date : | June 2015 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 0.9% sodium chloride
Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
|
Other: 0.9% sodium chloride |
|
Active Comparator: Physiologically balanced fluid
Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
|
Other: Physiologically balanced fluid
Other Name: Lactated ringers or Plasmalyte-A |
Primary Outcome Measures :
- Proportion of Isotonic Crystalloid Which is 0.9% Saline [ Time Frame: 30 days ]Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is 0.9% sodium chloride, censored at 30 days. The primary outcome was the proportion of intravenous isotonic crystalloid administered in the ICU that was saline. This was a continuous variable calculated for each patient as the volume of saline received divided by volume of saline received plus volume of balanced crystalloids received with a range from 0.0 (no saline received) to 1.0 (only saline received).
Secondary Outcome Measures :
- Proportion of Isotonic Crystalloid Which is Physiologically Balanced [ Time Frame: 30 days ]Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is either Lactated ringers or Plasmalyte-A, censored at 30 days.
- Total Intravenous Input [ Time Frame: 30 days ]Total volume of intravenous fluid administration during admission to the intensive care unit, censored at 30 days
- Total Isotonic Crystalloid Input [ Time Frame: 30 days ]Total volume of intravenous isotonic crystalloid administration during admission to the intensive care unit, censored at 30 days
- Total Intravenous Colloid Input [ Time Frame: 30 days ]Total volume of intravenous colloid administration (excluding blood products) during admission to the intensive care unit, censored at 30 days
- Total Intravenous Blood Product Administration [ Time Frame: 30 days ]Total volume of packed red blood cells, platelets, and fresh frozen plasma administered during admission to the intensive care unit, censored at 30 days
- Highest Serum Chloride Between Enrollment and Day 30 [ Time Frame: 30 days ]highest serum chloride (mmol/L) during admission to the intensive care unit, censored at 30 days
- Highest Serum Sodium Between Enrollment and Day 30 [ Time Frame: 30 days ]Highest serum sodium concentration (mmol/L) during admission to the intensive care unit, censored at 30 days
- Lowest Bicarbonate Concentration Between Enrollment and Day 30 [ Time Frame: 30 days ]Lowest serum bicarbonate concentration (mmol/L) during admission to the intensive care unit, censored at 30 days
- Number of Patients With MAKE30 [ Time Frame: 30 days ]Incidence of Major Adverse Kidney Events by 30 days -- a composite outcome defined as one or more of the following: death, new use of renal replacement therapy, or persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline)
- In-hospital Mortality [ Time Frame: 30 days ]Death prior to the earlier of hospital discharge or day 30
- New Use of Renal Replacement Therapy [ Time Frame: 30 days ]Receipt of new renal replacement therapy after the first study day, censored at 30 days
- Persistent Renal Dysfunction [ Time Frame: 30 days ]Persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline)
- Number of Contraindications [ Time Frame: 30 days ]Number of contraindications to assigned study fluid identified by providers, censored at 30 days
- Incidence of Hyperchloremia [ Time Frame: 30 days ]Incidence of hyperchloremia defined as a serum chloride greater than or equal to 110 mmol/L
- Incidence of Severe Hypochloremia [ Time Frame: 30 days ]Incidence of severe hypochloremia defined as a serum chloride less than 90mmol/L
- Increase in Serum Creatinine [ Time Frame: 30 days ]Increase in serum creatinine during hospitalization, censored at 30 days Change from baseline to highest value, median (IQR), mg/dl
- Incidence of Acute Kidney Injury [ Time Frame: 30 days ]Incidence of stage II or III acute kidney injury by Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury criteria, censored at 30 days
- Intensive Care Unit Free Days to Day 28 [ Time Frame: 28 days ]ICU-free days to 28 days after enrollment will be defined as the number of days alive and not admitted to an intensive care unit service after the patient's final discharge from the intensive care unit before 28 days. If the patient is admitted to an intensive care unit service at day 28 or dies prior to day 28, ICU-free days will be 0.
- Ventilator-free Days (VFD) to Day 28 [ Time Frame: 28 days ]Ventilator-free days to day 28 will be defined as the number of days alive and with unassisted breathing to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing. If a patient returns to assisted breathing and subsequently achieves unassisted breathing prior to day 28, VFD will be counted from the end of the last period of assisted breathing to day 28. If the patient is receiving assisted ventilation at day 28 or dies prior to day 28, VFD will be 0.
- Dialysis-free Survival to Day 28 [ Time Frame: 28 days ]Dialysis free survival to day 28 will be defined as the number of days alive and without dialysis receipt to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after last receipt of dialysis and remains free of dialysis. If the patient is receiving dialysis at day 28 or dies prior to day 28, VFD will be 0.
- Peak Creatinine in the First 30 Days [ Time Frame: 30 days ]Highest creatinine value in the first 30 days
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Admitted to the adult medical intensive care unit (MICU) at Vanderbilt University Medical Center
Exclusion Criteria:
- Age<18 years old
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02345486
Locations
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37209 | |
Sponsors and Collaborators
Vanderbilt University
Investigators
| Principal Investigator: | Todd W Rice, M.D., M.Sc. | Vanderbilt University Medical Center |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Todd Rice, Assistant Professor of Medicine, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT02345486 |
| Other Study ID Numbers: |
141349 |
| First Posted: | January 26, 2015 Key Record Dates |
| Results First Posted: | October 25, 2019 |
| Last Update Posted: | November 13, 2019 |
| Last Verified: | October 2019 |
Keywords provided by Todd Rice, Vanderbilt University:
|
Pilot Projects Plasmalyte A Ringer's lactate |
Sodium Chloride Critical Care Resuscitation" |
Additional relevant MeSH terms:
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases |
Plasma-lyte 148 Ophthalmic Solutions Pharmaceutical Solutions |